X4 Pharmaceuticals (XFOR) Non-Current Debt (2017 - 2019)

X4 Pharmaceuticals has reported Non-Current Debt for 3 years, with the latest figure at $22.2 million in Q2 2019.

• For the quarter ending Q2 2019, Non-Current Debt rose 188.06% year-over-year to $22.2 million; the trailing twelve-month figure through Jun 2019 stood at $22.2 million (up 188.06% YoY), and the FY2018 full-year result was $8.3 million, down 16.22% from the prior year.
• Non-Current Debt for Q2 2019 stood at $22.2 million, up from $8.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $22.2 million in Q2 2019, with the low at $7.7 million in Q2 2018.
• Historically, Non-Current Debt has averaged $10.9 million across 3 years, with a median of $9.0 million in 2018.
• Annual changes were most pronounced in 2018 — Non-Current Debt slipped 16.22% — and 2019, when it jumped 188.06%.
• X4 Pharmaceuticals' Non-Current Debt stood at $9.9 million in 2017, then declined by 16.22% to $8.3 million in 2018, then jumped by 167.03% to $22.2 million in 2019.
• The last three Non-Current Debt figures came in at $22.2 million (Q2 2019), $8.3 million (Q4 2018), and $7.8 million (Q3 2018), per Business Quant data.